ELEKTA (EKTAY) Downgraded to “Neutral” at J P Morgan Chase & Co

J P Morgan Chase & Co lowered shares of ELEKTA (NASDAQ:EKTAY) from an overweight rating to a neutral rating in a report released on Monday morning.

Separately, Zacks Investment Research downgraded shares of ELEKTA from a buy rating to a hold rating in a report on Friday, October 27th.

ELEKTA (NASDAQ:EKTAY) traded up $0.27 on Monday, hitting $8.65. 18,079 shares of the stock traded hands, compared to its average volume of 3,710. ELEKTA has a 12-month low of $7.97 and a 12-month high of $11.18.

TRADEMARK VIOLATION WARNING: This article was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2017/11/14/elekta-ektay-downgraded-to-neutral-at-j-p-morgan-chase-co.html.

ELEKTA Company Profile

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.

Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply